Beam Therapeutics (BEAM) awards 20,000 RSUs to SVP Bethany Cavanagh

Rhea-AI Filing Summary

Cavanagh Bethany J reported acquisition or exercise transactions in this Form 4 filing.

Beam Therapeutics reported that SVP, Finance and Treasurer Bethany J. Cavanagh received a grant of 20,000 restricted stock units under the company’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and vests in four equal annual installments, subject to continued service. Following this award, she holds 54,813 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cavanagh Bethany J

Role SVP, Finance and Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	20,000	$0.00	--

Holdings After Transaction: Common Stock — 54,813 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 20,000 RSUs Post-transaction holdings: 54,813 shares Vesting schedule: 4 annual installments +1 more

4 metrics

RSU grant size 20,000 RSUs Equity award to SVP, Finance and Treasurer

Post-transaction holdings 54,813 shares Total common stock held directly after grant

Vesting schedule 4 annual installments RSUs vest over first four anniversaries of grant

Grant price per RSU $0.0000 per unit Compensation award, not an open-market purchase

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, contingent right, vest

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"

contingent right financial

"Each RSU represents the contingent right to receive one share"

vest financial

"The RSUs vest in four substantially equal installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavanagh Bethany J

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		20,000(1)	A	$0	54,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BEAM report for Bethany J. Cavanagh?

Beam Therapeutics reported that SVP, Finance and Treasurer Bethany J. Cavanagh received 20,000 restricted stock units as an equity award. These RSUs were granted under the 2019 Equity Incentive Plan and increase her direct holdings to 54,813 shares of common stock.

How many Beam Therapeutics shares does Bethany J. Cavanagh hold after this Form 4?

After the reported grant, Bethany J. Cavanagh directly holds 54,813 shares of Beam Therapeutics common stock. This total includes the 20,000 newly granted restricted stock units, which convert into shares as they vest over the four-year schedule described in the footnote.

What are the terms of Bethany Cavanagh’s 20,000 BEAM RSU grant?

The 20,000 RSUs granted to Bethany Cavanagh each represent the right to receive one Beam Therapeutics common share. They vest in four substantially equal installments on each of the first four anniversaries of the grant date, conditioned on her continued service with the company.

Is Bethany Cavanagh’s BEAM Form 4 transaction a purchase or a compensation grant?

The Form 4 shows a compensation-related grant, not an open-market purchase. Bethany Cavanagh received 20,000 restricted stock units at a price of $0.0000 per unit, reflecting an award under Beam Therapeutics’ 2019 Equity Incentive Plan rather than a cash transaction in the market.

How do the BEAM RSUs granted to Bethany Cavanagh convert into common stock?

Each RSU granted to Bethany Cavanagh represents a contingent right to receive one share of Beam Therapeutics common stock. As the RSUs vest in four equal annual installments, and if she remains in service, the vested units settle into shares that increase her actual share ownership.

What plan governs Bethany Cavanagh’s 20,000 BEAM restricted stock units?

The 20,000 restricted stock units granted to Bethany Cavanagh were issued under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. This plan provides equity-based compensation, such as RSUs, to employees and typically includes vesting conditions tied to ongoing service with the company.